Add-Back Therapy Initiation with GnRH Agonist Treatment

Optimal Timing for Add-Back Therapy Initiation

The American College of Obstetricians and Gynecologists recommends adding add-back therapy to reduce or eliminate GnRH-induced bone mineral loss without reducing efficacy of pain relief when relief of pain from GnRH agonist treatment supports continued therapy 1
Expense and insurance coverage issues, difficulty coordinating administration timing, and urgent need for therapy may preclude concurrent initiation of add-back therapy with the first GnRH agonist injection, as noted by the Arthritis and Rheumatology guideline 2

No relevant facts are available due to ignored references
The American College of Obstetricians and Gynecologists recommends adding add-back therapy to reduce or eliminate GnRH-induced bone mineral loss without reducing efficacy of pain relief when relief of pain from GnRH agonist treatment supports continued therapy, and notes that delaying initiation beyond the first few weeks increases vasomotor symptoms and bone loss without providing additional therapeutic benefit 1

Add-back therapy with low doses of estrogen and progestin is essential when using elagolix to mitigate hypoestrogenic side effects while maintaining therapeutic efficacy for conditions like endometriosis and uterine fibroids, as recommended by the American College of Radiology 3
The combination of add-back therapy with elagolix allows for suppression of endogenous ovarian sex-steroid production while minimizing side effects, with evidence from Environmental Health Perspectives 4

Elagolix as monotherapy causes significant hypoestrogenic effects, including hot flashes 4, headaches 3, vaginal dryness 5, and hypertension 3
Without add-back therapy, approximately 1% of bone mass is lost per month after the onset of hypoestrogenism, according to Environmental Health Perspectives 4

The American College of Obstetricians and Gynecologists (ACOG) recommends add-back therapy when using GnRH agonists for endometriosis pain management, as stated in American Family Physician 5
Add-back therapy is FDA-approved in combination with elagolix for fibroid-related heavy menstrual bleeding, as noted in the Journal of the American College of Radiology 3
Estradiol levels should be monitored in premenopausal women treated with GnRH agonists and add-back therapy using high-sensitivity assays, according to the Journal of Clinical Oncology 6

Add-back regimens increase the overall cost of therapy but are essential for long-term management, as discussed in Environmental Health Perspectives 4